查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1239516

肌張力障礙治療市場：按藥物類型、給藥途徑和分銷渠道分類：2021-2031 年全球機遇分析和行業預測

Dystonia Drugs Market By Drug Type, By Route of Administration, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日期: | 出版商: Allied Market Research | 英文 210 Pages | 商品交期: 2-3個工作天內

價格

2021 年全球肌張力障礙治療市場價值 8.0667 億美元，從 2022-2031 年以 5.5% 的複合年增長率增長到 2031 年的 13.7867 億美元，預計將達到美元。

肌張力障礙有時被定義為一種運動障礙，其特徵是肌肉不自主收縮，導致重複和扭曲運動。 該病症可能影響身體的一個部位（局灶性肌張力障礙）、兩個部位（節段性肌張力障礙）或全身，稱為全身性肌張力障礙。 這些肌肉收縮從輕微到嚴重不等，並且會因姿勢異常而影響人的運動。 也有人說，女性比男性更容易患上這種疾病。 肌張力障礙的症狀包括腿部抽筋、不自覺地拉脖子、眨眼和說不出話來。 由於持續的肌肉收縮，它還會引起疼痛和不適。 然而，肌張力障礙沒有特定的原因，並且已知是由於與基底神經節相關的問題導致人類肌肉收縮而發生的。

肌張力障礙可以通過肉毒桿菌毒素 (Botox) 注射、幾種藥物和手術治療。 這些方法可以單獨或組合用於治療肌張力障礙。 用於治療肌張力障礙的藥物包括肌肉鬆弛劑、抗膽鹼能藥、抗驚厥藥和多巴胺能藥物。 對這些藥物的反應因人而異，並且可能因症狀的嚴重程度而異。

推動肌張力障礙治療市場增長的主要因素包括發達國家和新興市場肌張力障礙發病率的增加，以及帕金森病和亨廷頓舞蹈病等疾病的患病率增加。. 例如，根據帕金森基金會的數據，美國每年有近 9 萬人被診斷出患有帕金森病，全世界有超過 1000 萬人患有帕金森病。 帕金森病和肌張力障礙彼此密切相關，帕金森病患病率的增加增加了肌張力障礙的發病率。 這將進一步增加對肌張力障礙療法的需求，推動肌張力障礙療法市場的增長。

內容

第一章介紹

第 2 章執行摘要

第 3 章市場概述

  • 市場定義和範圍
  • 主要發現
    • 主要影響因素
    • 主要投資機會
  • 波特的五力分析
    • 供應商的議價能力
    • 買家的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 中等強度的競爭
  • 市場動態
    • 司機
      • 增加製藥領域的研發活動
      • 肌張力障礙的發生率增加
      • 神經系統疾病的患病率增加
    • 約束因素
      • 發展中國家缺乏對肌張力障礙的認識
    • 機會
      • 新興市場的增長機會
  • 分析 COVID-19 對市場的影響

第 4 章。肌張力障礙藥物市場：按藥物類型分類

  • 概覽
    • 市場規模和預測
  • 多巴胺激動劑
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • GABA 激動劑
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 抗驚厥藥
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 其他
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類

第 5 章肌張力障礙藥物市場：按給藥途徑

  • 概覽
    • 市場規模和預測
  • 口語
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 可注射
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類

第 6 章肌張力障礙藥物市場：按分銷渠道

  • 概覽
    • 市場規模和預測
  • 醫院藥房
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 在線提供商
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 藥店和零售藥店
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類

第 7 章肌張力障礙藥物市場：按地區

  • 概覽
    • 市場規模和預測：按地區
  • 北美
    • 主要趨勢和機會
    • 市場規模和預測：按藥物分類
    • 市場規模和按給藥途徑預測
    • 按分銷渠道劃分的市場規模和預測
    • 市場規模和預測：按國家/地區分類
      • 美國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物分類
      • 市場規模和按給藥途徑預測
      • 按分銷渠道劃分的市場規模和預測
      • 加拿大
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物分類
      • 市場規模和按給藥途徑預測
      • 按分銷渠道劃分的市場規模和預測
      • 墨西哥
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物分類
      • 市場規模和按給藥途徑預測
      • 按分銷渠道劃分的市場規模和預測
  • 歐洲
    • 主要趨勢和機會
    • 市場規模和預測：按藥物分類
    • 市場規模和按給藥途徑預測
    • 按分銷渠道劃分的市場規模和預測
    • 市場規模和預測：按國家/地區分類
      • 德國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物分類
      • 市場規模和按給藥途徑預測
      • 按分銷渠道劃分的市場規模和預測
      • 法國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物分類
      • 市場規模和按給藥途徑預測
      • 按分銷渠道劃分的市場規模和預測
      • 英國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物分類
      • 市場規模和按給藥途徑預測
      • 按分銷渠道劃分的市場規模和預測
      • 意大利
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物分類
      • 市場規模和按給藥途徑預測
      • 按分銷渠道劃分的市場規模和預測
      • 西班牙
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物分類
      • 市場規模和按給藥途徑預測
      • 按分銷渠道劃分的市場規模和預測
      • 其他歐洲
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物分類
      • 市場規模和按給藥途徑預測
      • 按分銷渠道劃分的市場規模和預測
  • 亞太地區
    • 主要趨勢和機會
    • 市場規模和預測：按藥物分類
    • 市場規模和按給藥途徑預測
    • 按分銷渠道劃分的市場規模和預測
    • 市場規模和預測：按國家/地區分類
      • 日本
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物分類
      • 市場規模和按給藥途徑預測
      • 按分銷渠道劃分的市場規模和預測
      • 中國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物分類
      • 市場規模和按給藥途徑預測
      • 按分銷渠道劃分的市場規模和預測
      • 澳大利亞
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物分類
      • 市場規模和按給藥途徑預測
      • 按分銷渠道劃分的市場規模和預測
      • 印度
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物分類
      • 市場規模和按給藥途徑預測
      • 按分銷渠道劃分的市場規模和預測
      • 韓國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物分類
      • 市場規模和按給藥途徑預測
      • 按分銷渠道劃分的市場規模和預測
      • 其他亞太地區
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物分類
      • 市場規模和按給藥途徑預測
      • 按分銷渠道劃分的市場規模和預測
  • 拉丁美洲/中東/非洲
    • 主要趨勢和機會
    • 市場規模和預測：按藥物分類
    • 市場規模和按給藥途徑預測
    • 按分銷渠道劃分的市場規模和預測
    • 市場規模和預測：按國家/地區分類
      • 巴西
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物分類
      • 市場規模和按給藥途徑預測
      • 按分銷渠道劃分的市場規模和預測
      • 沙特阿拉伯
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物分類
      • 市場規模和按給藥途徑預測
      • 按分銷渠道劃分的市場規模和預測
      • 南非
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物分類
      • 市場規模和按給藥途徑預測
      • 按分銷渠道劃分的市場規模和預測
      • 拉丁美洲其他地區/中東/非洲
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物分類
      • 市場規模和按給藥途徑預測
      • 按分銷渠道劃分的市場規模和預測

第八章競爭格局

  • 介紹
  • 關鍵成功策略
  • 10 家主要公司的產品映射
  • 比賽儀表板
  • 競爭熱圖
  • 定位頂級公司，2021 年

第九章公司簡介

  • Abbvie Inc
  • F. Hoffmann-La Roche Ltd.
  • Hameln Pharma Gmbh
  • Ipsen Pharma
  • Merz Pharmaceuticals, LLC
  • Novartis AG
  • Pfizer Inc.
  • Wellona Pharma
  • Teva Pharmaceutical Industries Limited
  • Amneal Pharmaceuticals LLC
Product Code: A13938

The global dystonia drugs market was valued at $806.67 million in 2021, and is projected to reach $1,378.67 million by 2031, registering a CAGR of 5.5% from 2022 to 2031. Dystonia may be defined as a movement disorder which is characterized by involuntary contraction of the muscles which causes repetitive or twisting movements. This condition may affect a single (focal dystonia) or two parts (segmental dystonia) of the body or can affect the whole body of the patient which is termed as (general dystonia). These muscle contractions can be mild or severe in nature and can affect the movement of the person due to abnormal posture. Moreover, women are more prone to the condition than the men. Symptoms of dystonia include the cramping of the foot, involuntary pulling of the neck, uncontrollable blinking, speech difficulties and others. People also suffer from pain and discomfort as a result of constant muscle contractions. However, dystonia does not have a specific cause but is known to occur as a result of problems related to basal ganglia which leads to muscle contractions in the person.  

Major approaches for treating dystonia include botulinum toxin (botox) injections, several drug types of medication and surgery. These approaches can be used individually or in combination for treating dystonia. In addition, the drugs used for the treatment of dystonia includes muscle relaxants, anticholinergic drugs, anticonvulsants, dopaminergic agents and others. The response to these medications depends on different individuals and may also differ according to the severity of the condition.  

The major factor driving the growth of dystonia drugs market includes the increase in incidences of dystonia in developed and developing regions, along with increase in prevalence of conditions such as Parkinson's disease, Huntington's disease and others. For instance, according to The Parkinson's Foundation, nearly 90,000 people in the U.S. are diagnosed with Parkinson's disease each year and more than 10 million people worldwide are living with Parkinson's disease. As Parkison's disease and dystonia are closely related to each other, increase in prevalence of Parkinsons diseases increases the incidence of dystonia. This further increases the demand for dystonia treatment drugs and thus, propels the growth of dystonia drugs market.  

In addition, major key players are offering a wide range of dystonia drug products with significant product differentiation. Manufacturers are focusing on developing novel formulations which are highly potent and effective and are easily accessible to the patients. Thus, increase in such product offering by the key market players is anticipated to increase the prescription of various dystonia medications by healthcare providers and patients and thereby augment the growth of the market.  

Furthermore, the increase in funding and investment by the key market players in the developing regions is boosting the market growth. Regions such as Asia-Pacific have been the point of attraction for the investors owing to the presence of essential resources in this region. Moreover, Asia-Pacific is emerging as a pharmaceutical hub for supply of medications and devices around the globe. This also propels the growth dystonia drugs market. 

Although various key factors are driving the growth of the market, there are few factors such as lack of awareness about the condition and its treatment options in underdeveloped countries is providing hindrance to the growth of the market. Dystonia is often left undiagnosed as people have less knowledge regarding the condition. Also, people in developing countries are unaware about the advanced treatment options available for dystonia. Also, availability of new alternate treatment options such as surgeries and other physical therapies, further acts as a restraint to the growth of the market.  

The global dystonia drugs market is segmented on the basis of drug type, distribution channel and region. By drug type, the market is categorized into dopaminergic agents, GABAergic agents, anticonvulsants, and others. On the basis of route of administration, the market is segmented into oral and injection. Based on distribution channel, the market is categorized into hospital pharmacies, online providers and drug stores and retail pharmacies. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA). 

Major Key players that operate in the global Dystonia Drugs Market are: AbbVie Inc., Amneal Pharmaceuticals LLC., F. Hoffmann-La Roche Ltd, Hameln Pharma GmbH, Ipsen Pharma, Merz Pharmaceuticals, LLC, Novartis AG, Pfizer Inc., Teva Pharmaceuticals and Wellona Pharma.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the dystonia drugs market analysis from 2021 to 2031 to identify the prevailing dystonia drugs market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the dystonia drugs market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global dystonia drugs market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Drug Type

  • Anticonvulsants drugs
  • Others
  • Dopaminergic agents
  • GABAergic agents

By Route of Administration

  • Oral
  • Injectable

By Distribution Channel

  • Hospital Pharmacies
  • Online Providers
  • Drug Stores and Retail Pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players

  • Hameln Pharma Gmbh
  • Ipsen Pharma
  • Novartis AG
  • Pfizer Inc.
  • Wellona Pharma
  • Teva Pharmaceutical Industries Limited
  • Amneal Pharmaceuticals LLC
  • F. Hoffmann-La Roche Ltd.
  • Merz Pharmaceuticals, LLC
  • Abbvie Inc

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Moderate bargaining power of suppliers
    • 3.3.2. Moderate bargaining power of buyers
    • 3.3.3. Moderate threat of substitutes
    • 3.3.4. Moderate threat of new entrants
    • 3.3.5. Moderate intensity of rivalry
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Increase in R&D activities in pharmaceutical field
      • 3.4.1.2. Increase in incidences of dystonia
      • 3.4.1.3. Increase in prevalence of neurological disorders
    • 3.4.2. Restraints
      • 3.4.2.1. Lack of awareness about dystonia in underdeveloped nations
    • 3.4.3. Opportunities
      • 3.4.3.1. Growth opportunity in emerging markets
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: DYSTONIA DRUGS MARKET, BY DRUG TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Dopaminergic agents
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. GABAergic agents
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Anticonvulsants drugs
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country
  • 4.5. Others
    • 4.5.1. Key market trends, growth factors and opportunities
    • 4.5.2. Market size and forecast, by region
    • 4.5.3. Market share analysis by country

CHAPTER 5: DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Oral
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Injectable
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country

CHAPTER 6: DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospital Pharmacies
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Online Providers
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Drug Stores and Retail Pharmacies
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: DYSTONIA DRUGS MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key trends and opportunities
    • 7.2.2. Market size and forecast, by Drug Type
    • 7.2.3. Market size and forecast, by Route of Administration
    • 7.2.4. Market size and forecast, by Distribution Channel
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Key market trends, growth factors and opportunities
      • 7.2.5.1.2. Market size and forecast, by Drug Type
      • 7.2.5.1.3. Market size and forecast, by Route of Administration
      • 7.2.5.1.4. Market size and forecast, by Distribution Channel
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Key market trends, growth factors and opportunities
      • 7.2.5.2.2. Market size and forecast, by Drug Type
      • 7.2.5.2.3. Market size and forecast, by Route of Administration
      • 7.2.5.2.4. Market size and forecast, by Distribution Channel
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Key market trends, growth factors and opportunities
      • 7.2.5.3.2. Market size and forecast, by Drug Type
      • 7.2.5.3.3. Market size and forecast, by Route of Administration
      • 7.2.5.3.4. Market size and forecast, by Distribution Channel
  • 7.3. Europe
    • 7.3.1. Key trends and opportunities
    • 7.3.2. Market size and forecast, by Drug Type
    • 7.3.3. Market size and forecast, by Route of Administration
    • 7.3.4. Market size and forecast, by Distribution Channel
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Key market trends, growth factors and opportunities
      • 7.3.5.1.2. Market size and forecast, by Drug Type
      • 7.3.5.1.3. Market size and forecast, by Route of Administration
      • 7.3.5.1.4. Market size and forecast, by Distribution Channel
      • 7.3.5.2. France
      • 7.3.5.2.1. Key market trends, growth factors and opportunities
      • 7.3.5.2.2. Market size and forecast, by Drug Type
      • 7.3.5.2.3. Market size and forecast, by Route of Administration
      • 7.3.5.2.4. Market size and forecast, by Distribution Channel
      • 7.3.5.3. UK
      • 7.3.5.3.1. Key market trends, growth factors and opportunities
      • 7.3.5.3.2. Market size and forecast, by Drug Type
      • 7.3.5.3.3. Market size and forecast, by Route of Administration
      • 7.3.5.3.4. Market size and forecast, by Distribution Channel
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Key market trends, growth factors and opportunities
      • 7.3.5.4.2. Market size and forecast, by Drug Type
      • 7.3.5.4.3. Market size and forecast, by Route of Administration
      • 7.3.5.4.4. Market size and forecast, by Distribution Channel
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Key market trends, growth factors and opportunities
      • 7.3.5.5.2. Market size and forecast, by Drug Type
      • 7.3.5.5.3. Market size and forecast, by Route of Administration
      • 7.3.5.5.4. Market size and forecast, by Distribution Channel
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Key market trends, growth factors and opportunities
      • 7.3.5.6.2. Market size and forecast, by Drug Type
      • 7.3.5.6.3. Market size and forecast, by Route of Administration
      • 7.3.5.6.4. Market size and forecast, by Distribution Channel
  • 7.4. Asia-Pacific
    • 7.4.1. Key trends and opportunities
    • 7.4.2. Market size and forecast, by Drug Type
    • 7.4.3. Market size and forecast, by Route of Administration
    • 7.4.4. Market size and forecast, by Distribution Channel
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Key market trends, growth factors and opportunities
      • 7.4.5.1.2. Market size and forecast, by Drug Type
      • 7.4.5.1.3. Market size and forecast, by Route of Administration
      • 7.4.5.1.4. Market size and forecast, by Distribution Channel
      • 7.4.5.2. China
      • 7.4.5.2.1. Key market trends, growth factors and opportunities
      • 7.4.5.2.2. Market size and forecast, by Drug Type
      • 7.4.5.2.3. Market size and forecast, by Route of Administration
      • 7.4.5.2.4. Market size and forecast, by Distribution Channel
      • 7.4.5.3. Australia
      • 7.4.5.3.1. Key market trends, growth factors and opportunities
      • 7.4.5.3.2. Market size and forecast, by Drug Type
      • 7.4.5.3.3. Market size and forecast, by Route of Administration
      • 7.4.5.3.4. Market size and forecast, by Distribution Channel
      • 7.4.5.4. India
      • 7.4.5.4.1. Key market trends, growth factors and opportunities
      • 7.4.5.4.2. Market size and forecast, by Drug Type
      • 7.4.5.4.3. Market size and forecast, by Route of Administration
      • 7.4.5.4.4. Market size and forecast, by Distribution Channel
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Key market trends, growth factors and opportunities
      • 7.4.5.5.2. Market size and forecast, by Drug Type
      • 7.4.5.5.3. Market size and forecast, by Route of Administration
      • 7.4.5.5.4. Market size and forecast, by Distribution Channel
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Key market trends, growth factors and opportunities
      • 7.4.5.6.2. Market size and forecast, by Drug Type
      • 7.4.5.6.3. Market size and forecast, by Route of Administration
      • 7.4.5.6.4. Market size and forecast, by Distribution Channel
  • 7.5. LAMEA
    • 7.5.1. Key trends and opportunities
    • 7.5.2. Market size and forecast, by Drug Type
    • 7.5.3. Market size and forecast, by Route of Administration
    • 7.5.4. Market size and forecast, by Distribution Channel
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Key market trends, growth factors and opportunities
      • 7.5.5.1.2. Market size and forecast, by Drug Type
      • 7.5.5.1.3. Market size and forecast, by Route of Administration
      • 7.5.5.1.4. Market size and forecast, by Distribution Channel
      • 7.5.5.2. Saudi Arabia
      • 7.5.5.2.1. Key market trends, growth factors and opportunities
      • 7.5.5.2.2. Market size and forecast, by Drug Type
      • 7.5.5.2.3. Market size and forecast, by Route of Administration
      • 7.5.5.2.4. Market size and forecast, by Distribution Channel
      • 7.5.5.3. South Africa
      • 7.5.5.3.1. Key market trends, growth factors and opportunities
      • 7.5.5.3.2. Market size and forecast, by Drug Type
      • 7.5.5.3.3. Market size and forecast, by Route of Administration
      • 7.5.5.3.4. Market size and forecast, by Distribution Channel
      • 7.5.5.4. Rest of LAMEA
      • 7.5.5.4.1. Key market trends, growth factors and opportunities
      • 7.5.5.4.2. Market size and forecast, by Drug Type
      • 7.5.5.4.3. Market size and forecast, by Route of Administration
      • 7.5.5.4.4. Market size and forecast, by Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top player positioning, 2021

CHAPTER 9: COMPANY PROFILES

  • 9.1. Abbvie Inc
    • 9.1.1. Company overview
    • 9.1.2. Key Executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
    • 9.1.7. Key strategic moves and developments
  • 9.2. F. Hoffmann-La Roche Ltd.
    • 9.2.1. Company overview
    • 9.2.2. Key Executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
  • 9.3. Hameln Pharma Gmbh
    • 9.3.1. Company overview
    • 9.3.2. Key Executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
  • 9.4. Ipsen Pharma
    • 9.4.1. Company overview
    • 9.4.2. Key Executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
  • 9.5. Merz Pharmaceuticals, LLC
    • 9.5.1. Company overview
    • 9.5.2. Key Executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Key strategic moves and developments
  • 9.6. Novartis AG
    • 9.6.1. Company overview
    • 9.6.2. Key Executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Business performance
  • 9.7. Pfizer Inc.
    • 9.7.1. Company overview
    • 9.7.2. Key Executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
  • 9.8. Wellona Pharma
    • 9.8.1. Company overview
    • 9.8.2. Key Executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
  • 9.9. Teva Pharmaceutical Industries Limited
    • 9.9.1. Company overview
    • 9.9.2. Key Executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
  • 9.10. Amneal Pharmaceuticals LLC
    • 9.10.1. Company overview
    • 9.10.2. Key Executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance
    • 9.10.7. Key strategic moves and developments

LIST OF TABLES

  • TABLE 01. GLOBAL DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 02. DYSTONIA DRUGS MARKET FOR DOPAMINERGIC AGENTS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 03. DYSTONIA DRUGS MARKET FOR GABAERGIC AGENTS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 04. DYSTONIA DRUGS MARKET FOR ANTICONVULSANTS DRUGS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 05. DYSTONIA DRUGS MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 06. GLOBAL DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 07. DYSTONIA DRUGS MARKET FOR ORAL, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 08. DYSTONIA DRUGS MARKET FOR INJECTABLE, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 09. GLOBAL DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 10. DYSTONIA DRUGS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 11. DYSTONIA DRUGS MARKET FOR ONLINE PROVIDERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 12. DYSTONIA DRUGS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 13. DYSTONIA DRUGS MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 14. NORTH AMERICA DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 15. NORTH AMERICA DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 16. NORTH AMERICA DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 17. NORTH AMERICA DYSTONIA DRUGS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 18. U.S. DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 19. U.S. DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 20. U.S. DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 21. CANADA DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 22. CANADA DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 23. CANADA DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 24. MEXICO DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 25. MEXICO DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 26. MEXICO DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 27. EUROPE DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 28. EUROPE DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 29. EUROPE DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 30. EUROPE DYSTONIA DRUGS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 31. GERMANY DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 32. GERMANY DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 33. GERMANY DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 34. FRANCE DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 35. FRANCE DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 36. FRANCE DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 37. UK DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 38. UK DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 39. UK DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 40. ITALY DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 41. ITALY DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 42. ITALY DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 43. SPAIN DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 44. SPAIN DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 45. SPAIN DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 46. REST OF EUROPE DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 47. REST OF EUROPE DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 48. REST OF EUROPE DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 49. ASIA-PACIFIC DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 50. ASIA-PACIFIC DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 51. ASIA-PACIFIC DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 52. ASIA-PACIFIC DYSTONIA DRUGS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 53. JAPAN DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 54. JAPAN DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 55. JAPAN DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 56. CHINA DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 57. CHINA DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 58. CHINA DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 59. AUSTRALIA DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 60. AUSTRALIA DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 61. AUSTRALIA DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 62. INDIA DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 63. INDIA DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 64. INDIA DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 65. SOUTH KOREA DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 66. SOUTH KOREA DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 67. SOUTH KOREA DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 68. REST OF ASIA-PACIFIC DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 69. REST OF ASIA-PACIFIC DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 70. REST OF ASIA-PACIFIC DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 71. LAMEA DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 72. LAMEA DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 73. LAMEA DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 74. LAMEA DYSTONIA DRUGS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 75. BRAZIL DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 76. BRAZIL DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 77. BRAZIL DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 78. SAUDI ARABIA DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 79. SAUDI ARABIA DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 80. SAUDI ARABIA DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 81. SOUTH AFRICA DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 82. SOUTH AFRICA DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 83. SOUTH AFRICA DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 84. REST OF LAMEA DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 85. REST OF LAMEA DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 86. REST OF LAMEA DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 87. ABBVIE INC: KEY EXECUTIVES
  • TABLE 88. ABBVIE INC: COMPANY SNAPSHOT
  • TABLE 89. ABBVIE INC: PRODUCT SEGMENTS
  • TABLE 90. ABBVIE INC: PRODUCT PORTFOLIO
  • TABLE 91. ABBVIE INC: KEY STRATERGIES
  • TABLE 92. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
  • TABLE 93. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
  • TABLE 94. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
  • TABLE 95. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
  • TABLE 96. HAMELN PHARMA GMBH: KEY EXECUTIVES
  • TABLE 97. HAMELN PHARMA GMBH: COMPANY SNAPSHOT
  • TABLE 98. HAMELN PHARMA GMBH: PRODUCT SEGMENTS
  • TABLE 99. HAMELN PHARMA GMBH: PRODUCT PORTFOLIO
  • TABLE 100. IPSEN PHARMA: KEY EXECUTIVES
  • TABLE 101. IPSEN PHARMA: COMPANY SNAPSHOT
  • TABLE 102. IPSEN PHARMA: PRODUCT SEGMENTS
  • TABLE 103. IPSEN PHARMA: PRODUCT PORTFOLIO
  • TABLE 104. MERZ PHARMACEUTICALS, LLC: KEY EXECUTIVES
  • TABLE 105. MERZ PHARMACEUTICALS, LLC: COMPANY SNAPSHOT
  • TABLE 106. MERZ PHARMACEUTICALS, LLC: PRODUCT SEGMENTS
  • TABLE 107. MERZ PHARMACEUTICALS, LLC: PRODUCT PORTFOLIO
  • TABLE 108. MERZ PHARMACEUTICALS, LLC: KEY STRATERGIES
  • TABLE 109. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 110. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 111. NOVARTIS AG: PRODUCT SEGMENTS
  • TABLE 112. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 113. PFIZER INC.: KEY EXECUTIVES
  • TABLE 114. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 115. PFIZER INC.: PRODUCT SEGMENTS
  • TABLE 116. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 117. WELLONA PHARMA: KEY EXECUTIVES
  • TABLE 118. WELLONA PHARMA: COMPANY SNAPSHOT
  • TABLE 119. WELLONA PHARMA: PRODUCT SEGMENTS
  • TABLE 120. WELLONA PHARMA: PRODUCT PORTFOLIO
  • TABLE 121. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY EXECUTIVES
  • TABLE 122. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
  • TABLE 123. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT SEGMENTS
  • TABLE 124. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
  • TABLE 125. AMNEAL PHARMACEUTICALS LLC: KEY EXECUTIVES
  • TABLE 126. AMNEAL PHARMACEUTICALS LLC: COMPANY SNAPSHOT
  • TABLE 127. AMNEAL PHARMACEUTICALS LLC: PRODUCT SEGMENTS
  • TABLE 128. AMNEAL PHARMACEUTICALS LLC: PRODUCT PORTFOLIO
  • TABLE 129. AMNEAL PHARMACEUTICALS LLC: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 01. DYSTONIA DRUGS MARKET, 2021-2031
  • FIGURE 02. SEGMENTATION OF DYSTONIA DRUGS MARKET, 2021-2031
  • FIGURE 03. TOP INVESTMENT POCKETS IN DYSTONIA DRUGS MARKET (2022-2031)
  • FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 06. MODERATE THREAT OF SUBSTITUTES
  • FIGURE 07. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 08. MODERATE INTENSITY OF RIVALRY
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALDYSTONIA DRUGS MARKET
  • FIGURE 10. DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF DYSTONIA DRUGS MARKET FOR DOPAMINERGIC AGENTS, BY COUNTRY 2021-2031(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF DYSTONIA DRUGS MARKET FOR GABAERGIC AGENTS, BY COUNTRY 2021-2031(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF DYSTONIA DRUGS MARKET FOR ANTICONVULSANTS DRUGS, BY COUNTRY 2021-2031(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF DYSTONIA DRUGS MARKET FOR OTHERS, BY COUNTRY 2021-2031(%)
  • FIGURE 15. DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF DYSTONIA DRUGS MARKET FOR ORAL, BY COUNTRY 2021-2031(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF DYSTONIA DRUGS MARKET FOR INJECTABLE, BY COUNTRY 2021-2031(%)
  • FIGURE 18. DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF DYSTONIA DRUGS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2021-2031(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF DYSTONIA DRUGS MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2021-2031(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF DYSTONIA DRUGS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY 2021-2031(%)
  • FIGURE 22. DYSTONIA DRUGS MARKET BY REGION, 2021
  • FIGURE 23. U.S. DYSTONIA DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 24. CANADA DYSTONIA DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 25. MEXICO DYSTONIA DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 26. GERMANY DYSTONIA DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 27. FRANCE DYSTONIA DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 28. UK DYSTONIA DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 29. ITALY DYSTONIA DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 30. SPAIN DYSTONIA DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 31. REST OF EUROPE DYSTONIA DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 32. JAPAN DYSTONIA DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 33. CHINA DYSTONIA DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 34. AUSTRALIA DYSTONIA DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 35. INDIA DYSTONIA DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 36. SOUTH KOREA DYSTONIA DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 37. REST OF ASIA-PACIFIC DYSTONIA DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 38. BRAZIL DYSTONIA DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 39. SAUDI ARABIA DYSTONIA DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 40. SOUTH AFRICA DYSTONIA DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 41. REST OF LAMEA DYSTONIA DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 42. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 43. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 44. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 45. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 46. COMPETITIVE DASHBOARD
  • FIGURE 47. COMPETITIVE HEATMAP: DYSTONIA DRUGS MARKET
  • FIGURE 48. TOP PLAYER POSITIONING, 2021
  • FIGURE 49. ABBVIE INC: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 50. ABBVIE INC: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 51. ABBVIE INC: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 52. F. HOFFMANN-LA ROCHE LTD.: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 53. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 54. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 55. IPSEN PHARMA: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 56. IPSEN PHARMA: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 57. IPSEN PHARMA: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 58. NOVARTIS AG: NET SALES, 2019-2021 ($MILLION)
  • FIGURE 59. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 60. NOVARTIS AG: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 61. PFIZER INC.: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 62. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 63. PFIZER INC.: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 64. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 65. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 66. AMNEAL PHARMACEUTICALS LLC: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 67. AMNEAL PHARMACEUTICALS LLC: REVENUE SHARE BY SEGMENT, 2021 (%)